Sp737
PANEL DISCUSSION
Date
May 8, 2023
Explore related products in the following collection:
Society: AGA
This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved. We will discuss AGA advocacy priorities, a model for removing barriers to high-value care in inflammatory bowel disease and GI, and how to most effectively engage in collaborative advocacy on behalf of the GI community.
This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved. We will discuss AGA advocacy priorities, a model for removing barriers to high-value care in inflammatory bowel disease and GI, and how to most effectively engage in collaborative advocacy on behalf of the GI community.
Presenters
University of Washington
Duke University School of Medicine
Stanford University Medical Center
University of Pennsylvania
Tracks
Related Products
REDUCING READMISSIONS FOR GI BLEEDING
This session is designed to demonstrate successful quality improvement in practices and across institutions with the focus on and meaningful real world implementation across a range of GI conditions…
NOVEL DIAGNOSTIC TOOLS AND METRICS FOR GERD: READY FOR PRIMETIME?
This session will provide an overview of the recent advances in diagnostic approaches to GERD, expansion in types and roles of diagnostic tools including ambulatory reflux monitoring, esophageal manometry, FLIP and MI in regards to GERD, and updates in guidelines and best practice advice…
Q&A
This session is designed to demonstrate successful quality improvement in practices and across institutions with the focus on and meaningful real world implementation across a range of GI conditions…
ANTI-TNF IN COMBINATION WITH LOW DOSE METHOTREXATE OUTPERFORMS ANTI-TNF MONOTHERAPY IN PATIENTS WITH PEDIATRIC CROHN'S DISEASE INITIATING ADALIMUMAB BUT NOT INFLIXIMAB
BACKGROUND: Tumor necrosis factor inhibitors (TNFi) are a mainstay of pediatric Crohn’s disease (PCD) therapy; yet not all patients respond, and others lose response over time. Combination therapy with methotrexate may improve response; however, this has not been rigorously evaluated…
